CL2011002268A1 - Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica. - Google Patents

Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica.

Info

Publication number
CL2011002268A1
CL2011002268A1 CL2011002268A CL2011002268A CL2011002268A1 CL 2011002268 A1 CL2011002268 A1 CL 2011002268A1 CL 2011002268 A CL2011002268 A CL 2011002268A CL 2011002268 A CL2011002268 A CL 2011002268A CL 2011002268 A1 CL2011002268 A1 CL 2011002268A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical
neurodegenerative
fatty acids
polyunsaturated fatty
Prior art date
Application number
CL2011002268A
Other languages
English (en)
Inventor
Ruiz Pablo Vicente Escribá
Xaubet Xavier Busquets
Jiménez Silvia Terés
Coblijn Gwendolyn Barceló
Cañellas Victoria Lladó
Etxenike Amaia Marcilla
María Laura Martín
Hurbano Mónica Higuera
Martínez Rafael Álvarez
Daniel Horacio López
Original Assignee
Lipopharma Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopharma Therapeutics S L filed Critical Lipopharma Therapeutics S L
Publication of CL2011002268A1 publication Critical patent/CL2011002268A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPUESTO DE FORMULA (I) COOR1-CHR2-(CH2) A-(CH=CH-CH2) B-(CH2) C-CH3 (I) DONDE A, B. C, R1 Y R2 TIENEN EL SIGNIFICADO INDICADO EN LA MEMORIA DESCRIPTIVA, COMPOSICIÓN FARMACÉUTICA QUE LO CONTIENE<br /> Y USO DE DICHO COMPUESTO COMO MEDICAMENTOS O ALIMENTOS FUNCIONALES PARA EL TRATAMIENTO O PREVENCIÓN DE ENFERMEDADES CUYA ETIOLOGÍA COMÚN ESTÁ BASADA EN ALTERACIONES (DE CUALQUIER ORIGEN) DE LOS LIPIDOS DE LA MEMBRANA CELULAR COMO, POR EJEMPLO, ALTERACIONES EN EL NIVEL, EN LA COMPOSICIÓN O EN LA ESTRUCTURA DE DICHOS LÍPIDOS. ASIMISMO, PARA ENFERMEDADES EN LAS QUE LA REGULACIÓN DE LA COMPOSICIÓN Y ESTRUCTURA LIPÍDICA DE MEMBRANA (O DE PROTEÍNAS QUE INTERACCIONAN CON ELLA) INDUZCA LA REVERSIÓN DEL ESTADO PATOLÓGICO.<br />  
CL2011002268A 2009-03-16 2011-09-13 Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica. CL2011002268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200900725A ES2345241B1 (es) 2009-03-16 2009-03-16 Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.

Publications (1)

Publication Number Publication Date
CL2011002268A1 true CL2011002268A1 (es) 2012-01-27

Family

ID=42673244

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002268A CL2011002268A1 (es) 2009-03-16 2011-09-13 Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica.

Country Status (18)

Country Link
US (7) US9161928B2 (es)
EP (2) EP3159329B1 (es)
JP (1) JP5904592B2 (es)
KR (4) KR20180021931A (es)
CN (4) CN109999018A (es)
AU (6) AU2010224749B2 (es)
BR (1) BRPI1009860A8 (es)
CA (1) CA2754963C (es)
CL (1) CL2011002268A1 (es)
DK (2) DK2409963T3 (es)
ES (3) ES2345241B1 (es)
HU (2) HUE051850T2 (es)
MX (1) MX2011009614A (es)
PL (1) PL2409963T3 (es)
PT (2) PT2409963T (es)
RU (1) RU2513995C2 (es)
SI (1) SI3159329T1 (es)
WO (1) WO2010106211A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
CA2777827C (en) 2009-10-30 2020-08-18 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
EP3689342A1 (en) 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2016062746A1 (en) * 2014-10-21 2016-04-28 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
JP6569919B2 (ja) * 2015-03-06 2019-09-04 国立大学法人 新潟大学 レビー小体型認知症のバイオマーカー
CA3005983A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
KR102569052B1 (ko) * 2017-05-16 2023-08-22 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합물
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
CN115052852A (zh) * 2020-01-29 2022-09-13 巴利阿里群岛大学 α-羟基化脂肪酸代谢产物、其医学用途以及作为生物标志物的用途
WO2021160650A1 (en) 2020-02-10 2021-08-19 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717816D0 (en) 1987-07-28 1987-09-03 Manchester Inst Science Tech Fabric testing apparatus
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH05974A (ja) * 1991-06-21 1993-01-08 Sagami Chem Res Center ハロゲン化不飽和アルキル化合物及びその前駆体
ES2161146B1 (es) * 1999-06-29 2002-07-01 Consejo Superior Investigacion Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas.
US6344574B1 (en) 2000-07-20 2002-02-05 The United States Of America As Represented By The Secretary Of Agriculture Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols
DE10106660A1 (de) * 2001-02-12 2002-08-29 Celanese Ventures Gmbh Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
WO2003084305A2 (en) * 2002-04-01 2003-10-16 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
JP2008540394A (ja) * 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
US8059805B2 (en) * 2005-06-30 2011-11-15 Emc Corporation Enhanced services provided using communication redirection and processing
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
DK1800675T3 (da) 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
KR101438177B1 (ko) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
RU2009120568A (ru) 2006-11-01 2010-12-10 Пронова Биофарма Норге Ас (No) Композиция
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

Also Published As

Publication number Publication date
US9907772B2 (en) 2018-03-06
EP3159329A1 (en) 2017-04-26
US20120108550A1 (en) 2012-05-03
JP5904592B2 (ja) 2016-04-13
KR20190018754A (ko) 2019-02-25
EP2409963B1 (en) 2017-01-04
PL2409963T3 (pl) 2017-05-31
AU2020205214A1 (en) 2020-07-30
EP3159329B1 (en) 2020-08-12
DK2409963T3 (en) 2017-02-27
ES2345241B1 (es) 2011-09-08
ES2345241A1 (es) 2010-09-17
CN106349058B (zh) 2020-01-14
AU2018203976A1 (en) 2018-06-21
JP2012520344A (ja) 2012-09-06
AU2010224749A1 (en) 2011-10-13
AU2016238970B2 (en) 2018-03-08
KR20110137365A (ko) 2011-12-22
AU2020205213A1 (en) 2020-07-30
PT2409963T (pt) 2017-02-15
ES2820025T3 (es) 2021-04-19
AU2020205214B2 (en) 2021-02-18
US9763906B2 (en) 2017-09-19
BRPI1009860A8 (pt) 2019-12-17
KR102233102B1 (ko) 2021-03-26
US10201515B2 (en) 2019-02-12
CN102356057A (zh) 2012-02-15
HUE051850T2 (hu) 2021-03-29
US20160158181A1 (en) 2016-06-09
US9763907B2 (en) 2017-09-19
HK1232207A1 (zh) 2018-01-05
AU2010224749B2 (en) 2016-07-07
WO2010106211A1 (es) 2010-09-23
US20170035720A1 (en) 2017-02-09
US20160158180A1 (en) 2016-06-09
US20190365690A1 (en) 2019-12-05
ES2613606T3 (es) 2017-05-24
US20180085332A1 (en) 2018-03-29
KR20180021931A (ko) 2018-03-05
AU2019226257B2 (en) 2020-05-07
DK3159329T3 (da) 2020-11-09
CN106349058A (zh) 2017-01-25
SI3159329T1 (sl) 2021-01-29
EP2409963A1 (en) 2012-01-25
KR20200024953A (ko) 2020-03-09
MX2011009614A (es) 2012-01-20
KR101833772B1 (ko) 2018-03-02
HUE032027T2 (en) 2017-08-28
US9161928B2 (en) 2015-10-20
AU2016238970A1 (en) 2016-11-03
US20200352891A1 (en) 2020-11-12
RU2513995C2 (ru) 2014-04-27
AU2019226257A1 (en) 2019-09-26
PT3159329T (pt) 2020-11-13
RU2011141850A (ru) 2013-04-27
CA2754963A1 (en) 2010-09-23
CN109999018A (zh) 2019-07-12
AU2018203976B2 (en) 2019-06-06
AU2020205213B2 (en) 2021-02-25
US11253497B2 (en) 2022-02-22
BRPI1009860A2 (pt) 2016-03-08
CN106420686A (zh) 2017-02-22
EP2409963A4 (en) 2013-10-02
CN106420686B (zh) 2020-05-22
CA2754963C (en) 2022-02-08

Similar Documents

Publication Publication Date Title
CL2011002268A1 (es) Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica.
CY1119784T1 (el) Ακετυλιωμενες σαλικυλικες ενωσεις λιπαρου οξεος και οι χρησεις αυτων
CY1119041T1 (el) Αλκοολικες συνθεσεις που παρουσιαζουν ελαττωμενο κινδυνο ακεταλδεϋδαιμιας
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
CR20120264A (es) Compuestos
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
UY33205A (es) Naftiridinas sustituidas y su uso como medicamentos
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
UY32092A (es) Nuevos compuestos para el tratamiento de trastornos del snc
CO6231001A2 (es) Estabilizacion de vitamina b12
SV2010003485A (es) Depsipeptidos ciclicos
PE20181493A1 (es) Profarmaco de adrenomedulina basado en polietilenglicol y su uso
GT201300254A (es) Triazolopiridinas
CO6741218A2 (es) Composición pesticida y procesos relacionados con el mismo
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
AR083772A1 (es) Metodos de tratamiento con compuestos de lipidos
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.